» Articles » PMID: 36531457

Sex- and Region-specific Associations of Skeletal Muscle Mass with Metabolic Dysfunction-associated Fatty Liver Disease

Overview
Specialty Endocrinology
Date 2022 Dec 19
PMID 36531457
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) is known to be the most common chronic liver disease worldwide, and accumulating evidence suggests that skeletal muscle might play an important role in metabolic health. However, the association between skeletal muscle and MAFLD is poorly understood so far. Therefore, we aimed to evaluate the associations of skeletal muscle with MAFLD and significant fibrosis.

Methods: A cross-sectional analysis was conducted using data obtained from the 2017-2018 US National Health and Nutrition Examination Survey. The whole-body, appendicular, and trunk skeletal muscle mass index (SMI) were assessed by dual-energy x-ray absorptiometry. MAFLD and significant fibrosis were assessed by transient elastography. Survey-weight adjusted multivariable logistic regressions were used to determine the associations. The area under the receiver operating characteristic curve (AUC) and variable importance scores from the random forest and logistic regression model were calculated to assess the predictive capability of variables and models.

Results: Of the 2065 participants, those with appendicular SMI in the highest quartile were associated with a lower risk for MAFLD in both sexes (male, OR[95%CI]: 0.46 [0.25~0.84]; female, OR[95%CI]: 0.32 [0.13~0.82]), but with a significantly different scale of the associations between sexes ( = 0.037). However, females with trunk SMI in the highest quartile had an increased risk of significant fibrosis (OR[95%CI]: 7.82 [1.86~32.77]). Trunk SMI and appendicular SMI ranked the third contributor to MAFLD in random forest and logistic regression models, respectively. Taking appendicular and trunk SMI into consideration, the AUCs for MAFLD were 0.890 and 0.866 in random forest and logistic regression models, respectively.

Discussion: The distribution of skeletal muscle mass differently affects MAFLD and significant fibrosis in the sex groups. Higher appendicular skeletal muscle mass was associated with a lower risk of MAFLD, while the risk of significant fibrosis in females was increased with the trunk skeletal muscle mass.

Citing Articles

Institutional Nomogram for Estimating Risk of Metabolic Associated Fatty Liver Disease (MAFLD).

Lv T, Tian J, Sun Y, Zhang Y, Qi F, Xiang L Diabetes Metab Syndr Obes. 2024; 17:3735-3752.

PMID: 39403553 PMC: 11472740. DOI: 10.2147/DMSO.S469677.


Association of muscle mass, grip strength and fat-to-muscle ratio and metabolic dysfunction-associated steatotic liver disease in a middle-to-elderly aged population.

Liu S, He Y, Yu G, Song C, Wang D, Liu L Ann Med. 2024; 56(1):2390169.

PMID: 39129458 PMC: 11321103. DOI: 10.1080/07853890.2024.2390169.


Metabolic-associated fatty liver disease and sarcopenia: A double whammy.

Viswanath A, Fouda S, Fernandez C, Pappachan J World J Hepatol. 2024; 16(2):152-163.

PMID: 38495287 PMC: 10941748. DOI: 10.4254/wjh.v16.i2.152.

References
1.
Kang M, Baek J, Kweon Y, Tak W, Jang S, Lee Y . Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver. Diagnostics (Basel). 2021; 11(6). PMC: 8227703. DOI: 10.3390/diagnostics11061061. View

2.
Ciardullo S, Perseghin G . Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021; 41(6):1290-1293. DOI: 10.1111/liv.14828. View

3.
Petermann-Rocha F, Gray S, Forrest E, Welsh P, Sattar N, Celis-Morales C . Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants. J Hepatol. 2022; 76(5):1021-1029. DOI: 10.1016/j.jhep.2022.01.010. View

4.
Larsson S, Back M, Rees J, Mason A, Burgess S . Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. Eur Heart J. 2019; 41(2):221-226. PMC: 6945523. DOI: 10.1093/eurheartj/ehz388. View

5.
Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View